Remove 2016 Remove Leads Remove Physicians
article thumbnail

HeartBeam Announces Acquisition of LIVMOR Assets

Legacy MEDSearch

Founded in 2016, LIVMOR developed the Halo+ Atrial Fibrillation (AF) Detection System, the world’s first FDA-cleared prescription wearable for continuous cardiac rhythm monitoring. The acquisition extends HeartBeam’s reach in remote monitoring and detection with full ownership of an existing cutting-edge FDA-cleared product.

article thumbnail

Leading in Pharma: a woman’s pathway

European Pharmaceutical Review

She founded COMPASS Pathways with her husband George Goldsmith in 2016, having experienced at first hand the challenges in accessing evidence-based and effective mental health care for a family member. I am a physician by training, and I worked in New York hospital emergency rooms for many years.

Leads 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Neglected tropical diseases: non-profits lead the way as private sectors lags

Pharmaceutical Technology

A key challenge in the development of treatments for such indications is the fact that these indications are neglected and often affect populations in lower-income countries, says Dr David Mabey an infectious disease physician at the London School of Hygiene & Tropical Medicine. For example, Merck & Co.

Leads 64
article thumbnail

Improving trial predictability: leveraging AI-powered analytics to guide trial design, strategy, and operations

pharmaphorum

Protocol design factors leading to operational challenges include design consistency, patient burden, site burden, study complexity, and eligibility criteria, including diversity and inclusion requirements. These potential study risks can lead to costly deviations and amendments, enrolment difficulties, and reduced patient compliance.

article thumbnail

Comparison of Humira biosimilars in the US and Europe

Pharmaceutical Technology

However, it has taken over six years for Amjevita to launch, after first being FDA-approved in 2016. Many other biosimilars have also been FDA-approved since 2016. In addition, two more Humira biosimilars are currently under FDA review and both are anticipated to launch in 2023.

article thumbnail

Redesigning Provider Incentives to Influence Practice Patterns and Performance

Clarify Health

Placing clinicians at financial risk for controlling health costs and improving quality without equipping them with the tools to do so leads to frustration and disillusionment. Physicians dislike being outliers and adjust their practice patterns to conform when provided with a relative social ranking. million on orthopedic MS-DRGs.[1]

article thumbnail

How Pharmacogenomics may finally realise its promise

pharmaphorum

In 2016, the estimated annual cost of drug-related morbidity and mortality resulting from non-optimised medication therapy was $528.4 The best way to do that is to target specific sub-populations, which will serve as a natural lead into personalised medicine becoming more mainstream. billion in the United States alone.